Blood test can help GPs spot ovarian cancer in women with suspicious symptoms

November 04, 2019

Glasgow, UK: Testing for levels of CA125 in the blood is a useful tool for gauging the likelihood of ovarian cancer and could help detect other types of cancer among patients in primary care, according to research presented at the 2019 NCRI Cancer Conference.

Although the CA125 test is already in use in countries around the world, this is the first large study to look at how well it performs in general practice for testing women who have possible symptoms of ovarian cancer.

Researchers say their results could guide women and their GPs on whether more invasive tests are needed to check for ovarian and other cancers. They also say that clinical guidelines could now be improved to ensure urgent referrals are made for women most at risk.

The research was led by Dr Garth Funston, a Clinical Research Fellow at the University of Cambridge, UK. He said: "Less than half of women with ovarian cancer survive for five years following diagnosis. The majority of women are not diagnosed until the disease is advanced, which makes it more difficult to cure.

"It's important that GPs have effective tools to detect ovarian cancer early and ensure patients are referred appropriately. While CA125 is widely used in general practice in the UK and internationally, prior to this study, it was unclear how effective a test it really was in general practice."

The research included data on 50,780 women who visited GPs in England with possible signs of ovarian cancer, such as persistent bloating or abdominal pain, and were tested for levels of CA125 in their blood between May 2011 and December 2014.

Researchers compared the results of these blood tests with data on which women were diagnosed with ovarian cancer or another form of cancer in the 12 months following their blood test.

They discovered that 10% of women who had an abnormally high level of CA125 in their blood were found to have ovarian cancer. This figure is much higher than previously thought and ten times higher than the estimate given in the UK's 2011 NICE (National Institute for Health and Care Excellence) guidelines on ovarian cancer diagnosis.

In women who had abnormal test results and were aged 50 years or older, 15% were found to have ovarian cancer, while in women under 50 with high CA125 levels, only 3% were diagnosed with ovarian cancer.

Results also showed that around 17% of women 50 years or older with an abnormal result were diagnosed with another form of the disease, such as pancreatic, lung or womb cancer.

The large size of the study meant that researchers were, for the first time, able to look in detail at women with different levels of CA125 in their blood in general practice and give more accurate estimates of cancer risk according to those levels.

The amount of CA125 in the blood is measured in units per millilitre (U/ml) and it can range from one to thousands. Dr Funston and his colleagues found, for example, that women with a CA125 level of 51 U/ml had a 3% probability of ovarian cancer. Three per cent is the level of risk at which NICE recommends urgent cancer referral.

Dr Funston said: "Our work shows that CA125 is a very useful test for detecting ovarian cancer in general practice.

"Our results can be used by doctors to determine the chance of a woman in general practice having ovarian cancer based on the CA125 level. This could help guide decisions made by GPs and their patients about the need for further investigation or referral.

"Our findings also highlight that women with symptoms who are aged 50 years or more and have abnormally high CA125 levels frequently have other types of cancer. It is really important that GPs are aware of this to ensure these cancers are not missed."

Dr Funston and his team continue their work on early diagnosis of ovarian cancer. Their study of CA125 blood testing forms part of efforts to create a prediction tool to help GPs spot women who may have the disease as early as possible.

Dr Shibani Nicum, Chair of NCRI's ovarian cancer subgroup and consultant medical oncologist at Oxford University Hospitals, who was not involved in the research said: "Diagnosing more cases of ovarian cancer at an early stage could have a big impact on survival and GPs are an essential part of that process.

"These findings could help doctors interpret test results and inform their decisions about which tests their patients need next. For instance, an older woman who has abnormal CA125 level should be considered high risk for ovarian cancer. Even if she does not turn out to have ovarian cancer, she might have another form of the disease and either way she will probably need an urgent referral.

"These finding can also be used to expand on existing clinical guidelines, both in the UK and other countries, to improve ovarian cancer diagnosis at the national and international level."
-end-


National Cancer Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.